{"commentary":{"count":48,"free_build_floor":8,"listing_floor":3,"by_channel":{"youtube":27,"podcast":20,"x_thread":1},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT05201547\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"DOMENICA","nct_id":"NCT05201547","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=domenica-nct05201547. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources"},"registry":{"acronym":"DOMENICA","arms":[{"description":null,"label":"Arm A: Dostarlimab 500 mg, every 3 weeks, 4 cycles and then 1000 mg every 6 weeks","type":"EXPERIMENTAL"},{"description":null,"label":"Arm B: Carboplatin AUC 5 or 6 plus Paclitaxel 175 mg/m2, every 3 weeks, 6 cycles.","type":"EXPERIMENTAL"}],"collaborators":["GlaxoSmithKline"],"completion_date":{"date":"2029-10","type":"ESTIMATED"},"conditions":["Endometrial Cancer"],"enrollment":{"count":260,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Carboplatin-Paclitaxel","type":"DRUG"},{"name":"Dostarlimab","type":"DRUG"}],"last_update":"2025-12-04","lead_sponsor":"ARCAGY/ GINECO GROUP","official_title":"Randomized Phase III Trial in MMR Deficient Endometrial Cancer Patients Comparing Chemotherapy Alone Versus Dostarlimab in First Line Advanced/Metastatic Setting","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2026-04","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Progression Free Survival (PFS)","timeFrame":"from the date of randomization until objective tumor progression based on RECIST 1.1, or death due to any cause, whichever occurs first assessed up to 5 years."}],"references":[{"citation":"Secord AA, Powell MA, McAlpine J. Molecular Characterization and Clinical Implications of Endometrial Cancer. Obstet Gynecol. 2025 Nov 1;146(5):660-671. doi: 10.1097/AOG.0000000000006080. Epub 2025 Sep 18.","pmid":"40966692","type":"DERIVED"},{"citation":"Cherifi F, Ray-Coquard I, Rubio MJ, Paoletti X, Lorusso D, Choi CH, Hasegawa K, Tan DSP, Hudson E, Davis A, Tognon G, Lheureux S, Vardar Key MA, Kurtz JE, Alexandre J, Joly F. DOMENICA: dostarlimab versus chemotherapy alone in first-line MMR-deficient advanced endometrial cancer patients. Future Oncol. 2025 Jun;21(13):1613-1623. doi: 10.1080/14796694.2025.2496133. Epub 2025 May 5.","pmid":"40323277","type":"DERIVED"}],"start_date":{"date":"2022-04-15","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Endometrial Cancer Patientes MMR Deficient Comparing Chemotherapy vs Dostarlimab in First Line","url":"https://clinicaltrials.gov/study/NCT05201547"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/domenica-nct05201547"}